12 Analysts Have This To Say About Sarepta Therapeutics
12 Analysts Have This To Say About Sarepta Therapeutics
12位分析師對Sarepta Therapeutics有這樣的看法
Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.
在過去的三個月中，有12位分析師對Sarepta Therapeutics（納斯達克股票代碼：SRPT）進行了評估，提供了從看漲到看跌的不同觀點。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00. This current average has increased by 3.76% from the previous average price target of $158.14.
分析師爲Sarepta Therapeutics設定了12個月的目標股價，顯示平均目標股價爲164.08美元，最高估計爲185.00美元，低估值爲128.00美元。目前的平均價格較之前的平均目標價158.14美元上漲了3.76％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
An in-depth...
對分析...
登入免費觀看全文
登入/註冊